EUZ Eckert & Ziegler Strahlen- und Medizintechnik AG

EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch
Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area

05.08.2024 / 15:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


August 5, 2024 - Berlin - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval, an additional 14 countries in the European Economic Area (EEA) will gain access to GalliaPharm®,once national approval procedures have been completed. Consequently, it will soon be the first generator for the production of Gallium-68 commercially available in the entire EEA.

"Over the past decade, diagnostics with Gallium-68-based drugs have experienced a huge growth, which we were able to actively influence with our GalliaPharm®," explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. "We are happy that our continued efforts to shape the landscape of nuclear medicine in Europe and around the world, are improving patient access and driving innovation forward."

Radionuclide generators offer a cost-effective alternative for the radiolabeling of biomolecules, which can be used in positron emission tomography (PET) or other applications. To date, radiolabeled products have mainly been a cancer diagnostic tool, with Gallium-68-based PET diagnostics being used primarily for tumors of the prostate or neuroendocrine system.

For other diseases, radioisotopes such as fluorine-18 are mostly used to radiolabel biomolecules. This requires millions to be invested in cyclotrons. The Ge-68/Ga-68 generator, on the other hand, has a compact size and can be purchased much more affordably. This reduces costs in nuclear medicine clinics and practices and increases flexibility.

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
/ /
Tel.: +49 (0) 30 / 94 10 84-138;

 



05.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 38
Fax:
Internet:
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1961253

 
End of News EQS News Service

1961253  05.08.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1961253&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
05/08/2024

Underlying

Reports on Eckert & Ziegler Strahlen- und Medizintechnik AG

 PRESS RELEASE

EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs

EQS-News: Eckert & Ziegler SE / Key word(s): Annual Results/Forecast Eckert & Ziegler: Record year 2024 with new all-time highs 27.03.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 27 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved a new record in the 2024 financial year with sales of € 295.8 million based on the preliminary annual financial statements*. Compared to the previous year, sales increased by almost € 50 million (+20%). EBIT before special items from continuing operations (adjusted EBIT)...

 PRESS RELEASE

EQS-News: Eckert & Ziegler: Rekordjahr 2024 mit neuen Höchstmarken

EQS-News: Eckert & Ziegler SE / Schlagwort(e): Jahresergebnis/Prognose Eckert & Ziegler: Rekordjahr 2024 mit neuen Höchstmarken 27.03.2025 / 07:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, den 27. März 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) erreichte auf Basis des vorläufigen Jahresabschlusses* im Geschäftsjahr 2024 mit einem Umsatz von 295,8 Mio. € eine neue Rekordmarke. Im Vergleich zum Vorjahr stieg der Umsatz um knapp 50 Mio. € (+20%). Das EBIT vor Sondereinflüssen aus fortgeführten Geschäftsbereic...

 PRESS RELEASE

EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-...

EQS-News: Eckert & Ziegler SE / Key word(s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, DE & New York, USA, 25 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s ...

 PRESS RELEASE

EQS-News: Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-2...

EQS-News: Eckert & Ziegler SE / Schlagwort(e): Vereinbarung/Auftragseingänge Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm 25.03.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, DE & New York, USA, 25. März 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) und Actinium Pharmaceuticals, Inc. gaben bekannt, dass sie eine Vereinbarung über die Lieferung von Actinium-225 (Ac-225) geschlossen haben. Mit dieser Vereinbarung erhält Actinium Pharmaceuticals Zugang...

 PRESS RELEASE

EQS-News: Eckert & Ziegler und AtomVie Global Radiopharma unterzeichne...

EQS-News: Eckert & Ziegler SE / Schlagwort(e): Auftragseingänge/Vereinbarung Eckert & Ziegler und AtomVie Global Radiopharma unterzeichnen weltweite Vereinbarung über die Lieferung von Lutetium-177 20.03.2025 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, DE & Hamilton, ON, CA, 20. März 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) und AtomVie Global Radiopharma Inc. (AtomVie) haben heute eine globale Liefervereinbarung bekannt gegeben. Eckert & Ziegler wird sein trägerfreies, qualitativ hochwertiges Lutetium-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch